TISIDB

Summary
Symbol	TNFSF13B
Name	tumor necrosis factor (ligand) superfamily, member 13b
Aliases	BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location	13q32-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane; Single-pass type II membrane protein.; SUBCELLULAR LOCATION: Tumor necrosis factor ligand superfamily member 13b, soluble form: Secreted.
Domain	PF00229 TNF(Tumour Necrosis Factor) family
Function	Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA. TNFSF13/APRIL binds to the same 2 receptors. Together, they form a 2 ligands -2 receptors pathway involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. A third B-cell specific BAFF-receptor (BAFFR/BR3) promotes the survival of mature B-cells and the B-cell response. ; FUNCTION: Isoform 2 seems to inhibit isoform 1 secretion and bioactivity. ; FUNCTION: Isoform 3: Acts as a transcription factor for its own parent gene, in association with NF-kappa-B p50 subunit, at least in autoimmune and proliferative B-cell diseases. The presence of Delta4BAFF is essential for soluble BAFF release by IFNG/IFN-gamma-stimulated monocytes and for B-cell survival. It can directly or indirectly regulate the differential expression of a large number of genes involved in the innate immune response and the regulation of apoptosis.

> Gene Ontology [ TOP ]
Biological Process	GO:0001776 leukocyte homeostasis GO:0001782 B cell homeostasis GO:0002250 adaptive immune response GO:0002260 lymphocyte homeostasis GO:0002377 immunoglobulin production GO:0002440 production of molecular mediator of immune response GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002467 germinal center formation GO:0002634 regulation of germinal center formation GO:0002636 positive regulation of germinal center formation GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0002819 regulation of adaptive immune response GO:0002821 positive regulation of adaptive immune response GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0007159 leukocyte cell-cell adhesion GO:0009306 protein secretion GO:0022407 regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0030888 regulation of B cell proliferation GO:0030890 positive regulation of B cell proliferation GO:0031294 lymphocyte costimulation GO:0031295 T cell costimulation GO:0031296 B cell costimulation GO:0032943 mononuclear cell proliferation GO:0032944 regulation of mononuclear cell proliferation GO:0032946 positive regulation of mononuclear cell proliferation GO:0033209 tumor necrosis factor-mediated signaling pathway GO:0034612 response to tumor necrosis factor GO:0042098 T cell proliferation GO:0042100 B cell proliferation GO:0042102 positive regulation of T cell proliferation GO:0042110 T cell activation GO:0042113 B cell activation GO:0042129 regulation of T cell proliferation GO:0045785 positive regulation of cell adhesion GO:0046651 lymphocyte proliferation GO:0048305 immunoglobulin secretion GO:0048872 homeostasis of number of cells GO:0050670 regulation of lymphocyte proliferation GO:0050671 positive regulation of lymphocyte proliferation GO:0050863 regulation of T cell activation GO:0050864 regulation of B cell activation GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050870 positive regulation of T cell activation GO:0050871 positive regulation of B cell activation GO:0051249 regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070661 leukocyte proliferation GO:0070663 regulation of leukocyte proliferation GO:0070665 positive regulation of leukocyte proliferation GO:0071356 cellular response to tumor necrosis factor GO:0071593 lymphocyte aggregation GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903039 positive regulation of leukocyte cell-cell adhesion
Molecular Function	GO:0005125 cytokine activity GO:0005126 cytokine receptor binding GO:0005164 tumor necrosis factor receptor binding GO:0032813 tumor necrosis factor receptor superfamily binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04060 Cytokine-cytokine receptor interaction hsa04064 NF-kappa B signaling pathway hsa04672 Intestinal immune network for IgA production
Reactome	R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-168256: Immune System R-HSA-5676594: TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway R-HSA-5668541: TNFR2 non-canonical NF-kB pathway R-HSA-5669034: TNFs bind their physiological receptors

Summary
Symbol	TNFSF13B
Name	tumor necrosis factor (ligand) superfamily, member 13b
Aliases	BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location	13q32-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TNFSF13B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between TNFSF13B and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
27364554	Melanoma; Lung carcinoma	Promote immunity (T cell function)	BAFF and APRIL derived from activin A-treated DCs upregulate proliferation and survival of T cells expressing the corresponding receptors, BAFF-R and TACI. In vivo, activin A-stimulated DCs demonstrate a significantly increased ability to induce tumor-specific CTLs and inhibit the growth of melanoma and lung carcinoma, which relies on DC-derived BAFF and APRIL, as knockdown of the BAFF and APRIL gene expression in activin A-treated DCs blocks augmentation of their antitumor potential.
19366834	Prostate carcinoma	Promote immunity	The transition from normal to neoplastic glands in prostate cancer (PCa) is marked by a dramatic decline of IL-7 and BAFF/BLyS production. These results suggest that epithelial IL-7 and BAFF/BLyS production support intraprostatic lymphocyte survival.
19755673	Chronic Lymphocytic Leukemia	Inhibit immunity	TCL1 x BAFF-Tg mice developed CLL-like disease at a significantly younger age and had more rapid disease progression and shorter survival than TCL1-Tg mice. Leukemia cells of TCL1 x BAFF-Tg mice had similar proportions of proliferating cells, but fewer proportions of dying cells, than did the CLL cells of TCL1-Tg mice. Moreover, leukemia cells from either TCL1 x BAFF-Tg or TCL1-Tg mice produced more aggressive disease when transferred into BAFF-Tg mice than into wild-type (WT) mice. Neutralization of CD257 resulted in rapid reduction in circulating leukemia cells.

Summary
Symbol	TNFSF13B
Name	tumor necrosis factor (ligand) superfamily, member 13b
Aliases	BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location	13q32-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TNFSF13B in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	TNFSF13B
Name	tumor necrosis factor (ligand) superfamily, member 13b
Aliases	BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location	13q32-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TNFSF13B in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.259	0.642
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.288	0.866
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.245	0.843
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.044	0.941
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.204	0.9
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.161	0.934
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.586	0.25
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.802	0.556
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.313	0.841
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.964	0.457
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.874	0.675
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.106	0.568

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TNFSF13B in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	14.3	0	14.3	0.196
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	0	25	0.222
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	TNFSF13B
Name	tumor necrosis factor (ligand) superfamily, member 13b
Aliases	BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location	13q32-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNFSF13B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TNFSF13B
Name	tumor necrosis factor (ligand) superfamily, member 13b
Aliases	BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location	13q32-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNFSF13B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNFSF13B. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TNFSF13B
Name	tumor necrosis factor (ligand) superfamily, member 13b
Aliases	BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location	13q32-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNFSF13B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TNFSF13B
Name	tumor necrosis factor (ligand) superfamily, member 13b
Aliases	BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location	13q32-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TNFSF13B expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TNFSF13B
Name	tumor necrosis factor (ligand) superfamily, member 13b
Aliases	BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location	13q32-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TNFSF13B and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TNFSF13B
Name	tumor necrosis factor (ligand) superfamily, member 13b
Aliases	BAFF; THANK; BLYS; TALL-1; TALL1; CD257; TNFSF20; ZTNF4; ApoL related ligand TALL-1; B-cell-activating facto ......
Chromosomal Location	13q32-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TNFSF13B collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting TNFSF13B.

ID	Name	Drug Type	Targets	#Targets
DB03316	1,4-Diethylene Dioxide	Small Molecule	EPN1, TGFB3, TNFSF13B	3
DB04272	Citric Acid	Small Molecule	AKR1B1, ANG, APRT, BHMT, C8G, CPB1, CS, CTDSP1, GNMT, HGS, HS3ST3A ......	23
DB08879	Belimumab	Biotech	TNFSF13B	1

Browse TNFSF13B